A recent secondary analysis of a randomized controlled trial has revealed that oral semaglutide (Rybelsus), a GLP-1 receptor agonist commonly used in diabetes management, significantly improves motivation in patients with major depressive disorder (MDD) and comorbid overweight or obesity. In the study involving 72 participants, those treated with semaglutide 14 mg demonstrated an increased willingness to exert physical effort when higher rewards were anticipated, as evidenced by a significant treatment × visit × expected value interaction (χ² = 12.024; P=0.02). Researchers, led by Rodrigo B. Mansur, MD, PhD, from the University of Toronto, reported reduced sensitivity to effort (β = -1.737, P=0.03) without altering sensitivity to probability (β = -0.776, P=0.51). This modulation of effort-based decision-making suggests that semaglutide may address anhedonia—a core MDD symptom involving diminished pleasure and motivation—by influencing reward-response pathways mediated by GLP-1 receptors. Notably, these findings challenge anecdotal concerns about “Ozempic personality,” where GLP-1 drugs are thought to dull responses to pleasurable activities; instead, the study indicates no harm to motivation and potential benefits in neuropsychiatric conditions with reward dysfunction.
Conducted over 16 weeks in a double-blind format, the trial recruited MDD patients with a BMI of 25 or higher from the Mood Disorders Psychopharmacology Unit, with participants randomized to semaglutide (titrated from 4 mg) or placebo alongside standard care. Motivation was assessed via keyboard-based tasks rewarding greater effort (e.g., using non-dominant hand) under varying reward conditions, showing semaglutide users were more inclined to tackle challenging tasks when rewards were substantial. Experts like Nina Kraguljac, MD, from the American Psychiatric Association, hailed the results as encouraging for anhedonia treatment but cautioned against immediate clinical changes, emphasizing the need for larger studies with diverse populations, brain imaging, and real-world applicability. Population data from Denmark and Sweden further reassure that GLP-1 agonists do not exacerbate psychiatric disorders like depression or anxiety. While the study was underpowered for overall antidepressant effects and task generalizability remains a limitation, it opens avenues for integrating metabolic therapies in psychiatry. For Indian doctors managing MDD in patients with metabolic comorbidities, this highlights semaglutide’s dual potential, though confirmation through rigorous trials is essential before broader adoption.
